MARKET

CRL

CRL

Charles River Lb
NYSE

Real-time Quotes | Nasdaq Last Sale

322.71
-6.36
-1.93%
After Hours: 322.71 0 0.00% 16:00 05/17 EDT
OPEN
329.46
PREV CLOSE
329.07
HIGH
330.70
LOW
320.98
VOLUME
814.49K
TURNOVER
--
52 WEEK HIGH
349.13
52 WEEK LOW
165.10
MARKET CAP
16.22B
P/E (TTM)
43.81
1D
5D
1M
3M
1Y
5Y
Mirabella Financial Services Llp Buys T-Mobile US Inc, VanEck Vectors Semiconductor ETF, CVS ...
GuruFocus News · 13h ago
Charles River Acquires Viral Vector Player For $350M
Benzinga · 13h ago
Charles River to acquire Vigene Biosciences for nearly $293 million in cash
Charles River Laboratories (CRL) announced an agreement to acquire Vigene Biosciences for $292.5M in cash. The deal also includes additional payments of up to $57.5M based on future performance.Subject to regulatory requirements
Seekingalpha · 19h ago
BRIEF-Charles River Laboratories To Acquire Vigene Biosciences For Purchase Price Of $292.5 Mln In Cash
reuters.com · 19h ago
Charles River Laboratories to Acquire Vigene Biosciences for $292.5 Million
MT Newswires · 23h ago
The 'new momentum' stocks to watch: Alpha Tactics
In the stock market, momentum tends to perform best in this stage of the recovery cycle, while "new momentum" has further room to run, UBS says.UBS strategist Keith Parker defines
Seekingalpha · 2d ago
Keybanc Maintains Overweight on Charles River, Raises Price Target to $360
Keybanc analyst Donald Hooker maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $340 to $360.
Benzinga · 3d ago
--KeyBanc Adjusts Price Target on Charles River Laboratories International to $360 From $340, Keeps Overweight Rating
MT Newswires · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRL. Analyze the recent business situations of Charles River Lb through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRL stock price target is 366.62 with a high estimate of 400.00 and a low estimate of 324.00.
EPS
Institutional Holdings
Institutions: 709
Institutional Holdings: 50.52M
% Owned: 100.53%
Shares Outstanding: 50.25M
TypeInstitutionsShares
Increased
148
2.53M
New
48
231.62K
Decreased
169
2.28M
Sold Out
37
167.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Foster
Chief Financial Officer/Executive Vice President
David Smith
Executive Vice President
William Barbo
Executive Vice President
Birgit Girshick
Executive Vice President
Joseph LaPlume
Senior Vice President/Chief Accounting Officer
Michael Knell
Lead Director/Independent Director
George Milne
Independent Director
Nancy Andrews
Independent Director
Robert Bertolini
Independent Director
Deborah Kochevar
Independent Director
George Llado
Independent Director
Martin Mackay
Independent Director
George Massaro
Independent Director
Richard Reese
Independent Director
Richard Wallman
Independent Director
Virginia Wilson
No Data
  • All
  • Financials
  • Insiders
More
About CRL
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Webull offers kinds of Charles River Laboratories Intl. Inc stock information, including NYSE:CRL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRL stock methods without spending real money on the virtual paper trading platform.